Sanofi Sheds Light On Plans For LixiLan, U300 At ADA
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi released positive data from two Phase III trials showing the next-generation insulin glargine U300 worked as well as Lantus in controlling blood sugar in patients with type 2 diabetes but with night-time benefits. The company also announced plans to initiate a Phase III trial studying a combination of the GLP-1 agonist Lyxumia with Lantus in the first half of 2014.